NCT05227131: Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received treatment with at least one HER2-targeting treatment regimen
Exclusions: Patients who have had more than three HER2-targeting treatment regimens in the metastatic setting; Patients who have not progressed on, or following, the most recent line of therapy; Patients with prior exposure to margetuximab, capecitabine, or other fluoropyrimidine [e.g., 5-fluorouracil] or any HER2 tyrosine kinase inhibitor (TKI) tucatinib, and/or dual HER2/epidermal growth factor receptor (EGFR) TKIs (lapatinib, neratinib, afatinib, etc.); Patients with active & progressing brain metastasis that require treatment; Patients with leptomeningeal disease

Comments are closed.

Up ↑